I wanted to talk about a few drugs that were created by funds from the Leukemia & Lymphoma Society and the donations that we are asking for. This will be a three-day series starting on May 3rd. Today’s post is on the drug Rituxan. Read below on how this drug is used for patients and the history of it. This information was pulled from the Leukemia & Lymphoma Society’s website at lls.org.
Rituxan®, a monoclonal antibody drug, was FDA approved for follicular non-Hodgkin lymphoma (NHL) patients in 1997. In fact, it was the very first targeted drug approved in the U.S. LLS-funded researchers found that Rituxan® can dramatically improve chemotherapy effectiveness, and the FDA approved Rituxan® to be used in combination with other chemotherapy drugs for people with follicular lymphoma and other non-Hodgkin lymphoma types. It’s contributed to a doubling of the survival rate for NHL patients, and is now also FDA approved as a treatment for patients with chronic lymphocytic leukemia or Hodgkin lymphoma.
To help fund researchers finding the cure for cancer and patients live a normal life donate to the Leukemia & Lymphoma Society.
Like this:
Be the first to like this post.